Historical perspectives and future directions of gene-modified T-cell therapy

Yoshiki Akatsuka

研究成果: Article

抄録

Adoptive immunotherapy using genetically modified T-cells is an emerging and promising treatment modality for various malignant diseases. The technology involves engineering of T-cells armed with well-characterized receptors such as T-cell receptors or chimeric antigen receptors. The latter is comprised of antibody/ligand and intracellular signaling domains. These molecules can be further modified to enhance their affinity, specificity, and several other functions. The success of adoptive immunotherapy is rooted in the application of extensive insights derived from allogeneic hematopoietic stem cell transplantations (HSCT). Herein, the historical perspectives of gene-modified T-cell therapy are discussed by comparison with the evolution of allogeneic HSCT. Furthermore, the prospects for the development and improvement of these powerful therapeutic methods are also highlighted.

元の言語English
ページ(範囲)2241-2249
ページ数9
ジャーナル[Rinsho ketsueki] The Japanese journal of clinical hematology
57
発行部数10
出版物ステータスPublished - 01-01-2016

Fingerprint

Cell- and Tissue-Based Therapy
Adoptive Immunotherapy
Hematopoietic Stem Cell Transplantation
T-Lymphocytes
Genes
Antigen Receptors
T-Cell Antigen Receptor
Ligands
Technology
Antibodies
Therapeutics
Direction compound

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

@article{674eaa7dc66a418a947ba7435b4a0f8b,
title = "Historical perspectives and future directions of gene-modified T-cell therapy",
abstract = "Adoptive immunotherapy using genetically modified T-cells is an emerging and promising treatment modality for various malignant diseases. The technology involves engineering of T-cells armed with well-characterized receptors such as T-cell receptors or chimeric antigen receptors. The latter is comprised of antibody/ligand and intracellular signaling domains. These molecules can be further modified to enhance their affinity, specificity, and several other functions. The success of adoptive immunotherapy is rooted in the application of extensive insights derived from allogeneic hematopoietic stem cell transplantations (HSCT). Herein, the historical perspectives of gene-modified T-cell therapy are discussed by comparison with the evolution of allogeneic HSCT. Furthermore, the prospects for the development and improvement of these powerful therapeutic methods are also highlighted.",
author = "Yoshiki Akatsuka",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "57",
pages = "2241--2249",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "10",

}

Historical perspectives and future directions of gene-modified T-cell therapy. / Akatsuka, Yoshiki.

:: [Rinsho ketsueki] The Japanese journal of clinical hematology, 巻 57, 番号 10, 01.01.2016, p. 2241-2249.

研究成果: Article

TY - JOUR

T1 - Historical perspectives and future directions of gene-modified T-cell therapy

AU - Akatsuka, Yoshiki

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Adoptive immunotherapy using genetically modified T-cells is an emerging and promising treatment modality for various malignant diseases. The technology involves engineering of T-cells armed with well-characterized receptors such as T-cell receptors or chimeric antigen receptors. The latter is comprised of antibody/ligand and intracellular signaling domains. These molecules can be further modified to enhance their affinity, specificity, and several other functions. The success of adoptive immunotherapy is rooted in the application of extensive insights derived from allogeneic hematopoietic stem cell transplantations (HSCT). Herein, the historical perspectives of gene-modified T-cell therapy are discussed by comparison with the evolution of allogeneic HSCT. Furthermore, the prospects for the development and improvement of these powerful therapeutic methods are also highlighted.

AB - Adoptive immunotherapy using genetically modified T-cells is an emerging and promising treatment modality for various malignant diseases. The technology involves engineering of T-cells armed with well-characterized receptors such as T-cell receptors or chimeric antigen receptors. The latter is comprised of antibody/ligand and intracellular signaling domains. These molecules can be further modified to enhance their affinity, specificity, and several other functions. The success of adoptive immunotherapy is rooted in the application of extensive insights derived from allogeneic hematopoietic stem cell transplantations (HSCT). Herein, the historical perspectives of gene-modified T-cell therapy are discussed by comparison with the evolution of allogeneic HSCT. Furthermore, the prospects for the development and improvement of these powerful therapeutic methods are also highlighted.

UR - http://www.scopus.com/inward/record.url?scp=85011949075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011949075&partnerID=8YFLogxK

M3 - Article

C2 - 27795536

AN - SCOPUS:85011949075

VL - 57

SP - 2241

EP - 2249

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 10

ER -